By Gary M. White, MD

Note, this is a brief summary only and is meant to emphasize dermatologic aspects. More complete information, including the package insert and recent studies should be consulted before prescribing.

Guselkumab is an interleukin-23 inhibitor FDA-approved for the treatment of psoriasis. Results show it to be highly effective. For example, in one study at 16 weeks, 91% of patients achieved a PASI 75% response.

Trade Name



TREMFYA is an interleukin-23 blocker indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.


Guselkumab 100 mg is given by subcutaneous injection at weeks 0, 4 and then every 8 weeks.

Side Effects

In one study, the rate of infections treated with antibiotics was lower than placebo. Injection-site reactions occur in a small percentage of patients.

From the package insert: Most common (≥1%) adverse reactions associated with TREMFYA include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.


Other Interactions

Avoid use of live vaccines in patients treated with TREMFYA.


JAAD 2017;76;418 Package Insert


Homepage | FAQs | Use of Images | Contact Dr. White

It is not the intention of to provide specific medical advice, diagnosis or treatment. only intends to provide users with information regarding various medical conditions for educational purposes and will not provide specific medical advice. Information on is not intended as a substitute for seeking medical treatment and you should always seek the advice of a qualified healthcare provider for diagnosis and for answers to your individual questions. Information contained on should never cause you to disregard professional medical advice or delay seeking treatment. If you live in the United States and believe you are having a medical emergency call 911 immediately.